PubMed · 15770779
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Stuart L Fine, Daniel F Martin, Peter Kirkpatrick. 2005. Pegaptanib sodium.. https://doi.org/10.1038/nrd1677
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
We demonstrate that aptamer-capped near-infrared PbS quantum dots (QDs) can detect a target protein based on selective charge transfer. The water-soluble QDs are synthesized with the thrombin-binding aptamer, which retains the secondary quadruplex structure necessary for binding to thrombin. These QDs have diameters of 3-6 nm and fluoresce around 1050 nm. When the aptamer-functionalized QD binds to its target, a fluorescence quenching occurs due to charge transfer from amine groups on the protein to the QD. Thrombin is detected within 1 min with a detection limit of approximately 1 nM. This selective detection is observed even in the presence of high background concentrations of interfering negatively or positively charged proteins, suggesting that aptamer-capped QDs could be useful for label-free protein assays.
The combination of specific ligand-binding aptamers with hairpin ribozyme catalysis generates molecules that can be controlled by external factors. Here we have generated hairpin ribozymes that can be regulated by a short DNA aptamer specific for human alpha-thrombin. This was achieved by constructing a ribozyme variant harboring an RNA sequence complementary to the aptamer, to which the aptamer can hybridize forming a heteroduplex. In this way, the DNA aptamer completely abolishes the catalytic activity of the ribozyme, due to the formation of an inactive ribozyme conformation. However, in the presence of the aptamer's target protein human alpha-thrombin, the inhibitory effect of the DNA aptamer is competitively neutralized and the ribozyme is activated in a highly specific fashion. Protein-responsive allosteric ribozymes are proposed to act as tools with potential applications in medicine where fast detection of clinically relevant targets is required.